High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing

Jun, Hye Ryeong; Kang, Hyun Ju; Ju, Sung Hun; Kim, Jung Eun; Jeon, Sang Youl; Ku, Bosung; Lee, Jae Jun; Kim, Min Soo; Kim, Min Jeong; Choi, Jung-Joo; Noh, Joseph J.; Kim, Hyun Soo; Lee, Jeong‐Won; Lee, Jin Ku; Lee, Dong Woo

doi:10.1016/j.biomaterials.2023.122087

Cited by 8 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, we developed a specialized chip that enabled the cultivation of small quantities of patient-derived cells. These cells were carefully embedded within hydrogels, such as Matrigel 8 . Second, we designed a disposable nozzle-type cell dispenser, facilitating the rapid and precise distribution of cells 8,9 .…”

Section: Codrp Generation and Establishmentmentioning

confidence: 99%

“…These cells were carefully embedded within hydrogels, such as Matrigel 8 . Second, we designed a disposable nozzle-type cell dispenser, facilitating the rapid and precise distribution of cells 8,9 . Additionally, we engineered a scanner with fluorescence-based imaging capabilities to measure drug responses accurately 10 .…”

Section: Codrp Generation and Establishmentmentioning

confidence: 99%

“…To overcome the aforementioned technical challenges, we have developed the cancer organoid-based diagnosis reactivity prediction (CODRP) platform, which includes a cell culture chip (Cellvitro® 384 pillar/ well plate, MBD Co., Ltd.) 8 capable of culturing cells at the nanoliter level, a cell dispenser (ASFA® spotter, MBD Co., Ltd.) 8,9 within a hydrogel for precise and rapid cell seeding, a fluorescence scanner (ASFA® scanner, MBD Co., Ltd.) 10 for measuring drug responses, and algorithms (CODRP PhenoSW, MBD Co., Ltd.) to enhance correspondence with clinical outcomes. In this study, we established a methodology for obtaining a large number of LCOs from pleural effusion (PE) samples from patients with lung cancer.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Lee,

Kim,

Lee

et al. 2024

npj Precis. Onc.

Self Cite

View full text Add to dashboard Cite

Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.

show abstract

Section: Codrp Generation and Establishmentmentioning

confidence: 99%

Section: Codrp Generation and Establishmentmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Lee,

Kim,

Lee

et al. 2024

npj Precis. Onc.

Self Cite

View full text Add to dashboard Cite

show abstract

“…68 Accordingly, organoids have been widely applied in organ development, precision medicine, regenerative medicine, and so on, serving as a valuable tool for researching a wide range of biological processes and diseases. [69][70][71] Furthermore, organoids are also being employed for CRC typing. For instance, epigenetic pattern alterations are a driving force behind tumor heterogeneity and carcinogenesis.…”

Section: Patient-derived Xenografts and Organoids Modelsmentioning

confidence: 99%

“…Organoids are three‐dimensional structures, miniaturized in vitro organ models that highly mimic genetic and epigenetic characteristics of target tissues or organs in vivo 68 . Accordingly, organoids have been widely applied in organ development, precision medicine, regenerative medicine, and so on, serving as a valuable tool for researching a wide range of biological processes and diseases 69–71 . Furthermore, organoids are also being employed for CRC typing.…”

Section: Preclinical and Clinical Evidence For Crc Subtypingmentioning

confidence: 99%

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Dang,

Zuo,

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is among the most hackneyed malignancies. Even patients with identical clinical symptoms and the same TNM stage still exhibit radically different clinical outcomes after receiving equivalent treatment regimens, indicating extensive heterogeneity of CRC. Myriad molecular subtypes of CRC have been exploited for decades, including the most compelling consensus molecular subtype (CMS) classification that has been broadly applied for patient stratification and biomarker‐drug combination formulation. Encountering barriers to clinical translation, however, CMS classification fails to fully reflect inter‐ or intra‐tumor heterogeneity of CRC. As a consequence, addressing heterogeneity and precisely managing CRC patients with unique characteristics remain arduous tasks for clinicians.ReviewIn this review, we systematically summarize molecular subtypes of CRC and further elaborate on their clinical applications, limitations, and future orientations.ConclusionIn recent years, exploration of subtypes through cell lines, animal models, patient‐derived xenografts (PDXs), organoids, and clinical trials contributes to refining biological insights and unraveling subtype‐specific therapies in CRC. Therapeutic interventions including nanotechnology, clustered regulatory interspaced short palindromic repeat/CRISPR‐associated nuclease 9 (CRISPR/Cas9), gut microbiome, and liquid biopsy are powerful tools with the possibility to shift the immunologic landscape and outlook for CRC precise medicine.

show abstract

Enhanced hepatotoxicity assessment through encapsulated HepG2 spheroids in gelatin hydrogel matrices: Bridging the gap from 2D to 3D culture

Park,

Koh,

Lee

2024

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing

Cited by 8 publications

References 56 publications

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Enhanced hepatotoxicity assessment through encapsulated HepG2 spheroids in gelatin hydrogel matrices: Bridging the gap from 2D to 3D culture

Contact Info

Product

Resources

About